随着年报披露季收官，辅助生殖龙头企业锦欣生殖引发资本市场广泛关注。近日，中金公司、华泰证券、光大证券、华兴证券等多家机构密集发布研报，普遍维持“买入”或“跑赢行业”评级，一致看好该公司在2026年的业绩复苏前景。 中金公司维持锦欣生殖“跑赢行业”评级，目标价3.50港元，随着深圳新院区产能释放、美国加州商保法案落地，以及公司自主研发的AI智能体覆盖诊疗全流程，技术壁垒不断夯实，预计规模效应将在2026年集中体现。华泰证券同样对锦欣生殖维持“买入”评级，目标价3.25港元。光大证券强调，锦欣生殖是中国最大的民营辅助生殖机构，成功率领先且维持稳定，维持“买入”评级。 同时，4月21日，锦欣生殖发布了“对股东的一封信”，强调公司目前聚焦中国内地业务，增加股东回报。数据显示，今年以来，锦欣生殖进行了多次股票回购，斥资逾3700万，并注销了前期已回购的超5200万股。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.